Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals reported a Q1 2026 net loss of $47.6 million, or $0.42 per share, with operating expenses decreasing year-over-year due to disciplined resource allocation. The company strengthened its balance sheet with the $180 million non-dilutive monetization of its Rare Pediatric Disease Priority Review Voucher, resulting in a pro forma cash position of approximately $322.6 million. This cash position is expected to fund operations into the second quarter of 2028, providing stability as it reinitiates dosing in the pivotal Phase 2 trial of RP-A501 for Danon disease.
Key figures
- Net loss
- 47600000
- Ga expenses
- 17100000
- Rd expenses
- 31500000
- Prv proceeds
- 180000000
- Cash position
- 144400000
- Pro forma cash
- 322600000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.